Verified Nov 2026
Other
·

Irvine, California
·
Since 2017
Tarsus Pharmaceuticals is a biopharmaceutical company headquartered in Irvine, California, founded in 2017, with 200–500 employees and estimated revenue of $250–500 million. The company develops and commercializes eye care treatments, including its FDA-approved product XDEMVY® for Demodex blepharitis, and maintains a pipeline addressing ocular rosacea, Lyme disease, and other conditions using its proprietary lotilaner platform.
Tarsus Pharmaceuticals, Inc. at a glance
Revenue
$250-500M
Est. band
Employees
200-500
Founded
2017
Headquarters
Irvine, California
Industries
Automotive
Electric Vehicles
Medical
Overview
Tarsus Pharmaceuticals is a biopharmaceutical company headquartered in Irvine, California, founded in 2017, with 200–500 employees and estimated revenue of $250–500 million. The company develops and commercializes eye care treatments, including its FDA-approved product XDEMVY® for Demodex blepharitis, and maintains a pipeline addressing ocular rosacea, Lyme disease, and other conditions using its proprietary lotilaner platform.
At a glance
Attribute | Detail |
|---|---|
Founded | 2017 |
Headquarters | Irvine, California |
Employees | 200-500 |
Revenue | $250-500M (estimated) |
What Tarsus Pharmaceuticals, Inc. makes
The company specializes in drug development and commercialization for eye diseases, leveraging a proprietary therapeutic platform targeting parasite-mediated conditions.
Latest developments
2026-11-05 — News Releases | Tarsus Pharmaceuticals (tarsusrx.com)
2026-11-04 — VM - Tarsus Pharmaceuticals Announces Q3 Financial Results, Achieves Record Sales for Xdemvy (visionmonday.com)
2026-09-04 — Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Tarsus Pharmaceuticals (gcs-web.com)
2026-08-06 — Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing | Tarsus Pharmaceuticals (tarsusrx.com)
2026-08-06 — Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position | Tarsus Pharmaceuticals (tarsusrx.com)
2026-08-06 — Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth | Tarsus Pharmaceuticals (tarsusrx.com)
Facilities
Tarsus Pharmaceuticals, Inc. is headquartered in Irvine, California. Public sources also reference these locations:
Irvine, California — pharmacompass.com
Company details
Tarsus reported record sales for XDEMVY® in the third quarter of 2026, serving patients, healthcare providers, and specialty pharmacies. Tarsus Pharmaceuticals, Inc. was founded in 2017, has an estimated 200-500 employees, and is headquartered in Irvine, California.
Frequently asked questions
What does Tarsus Pharmaceuticals, Inc. do?
Tarsus Pharmaceuticals is a biopharmaceutical company headquartered in Irvine, California, founded in 2017, with 200–500 employees and estimated revenue of $250–500 million. The company develops and commercializes eye care treatments, including its FDA-approved product XDEMVY® for Demodex blepharitis, and maintains a pipeline addressing ocular rosacea, Lyme disease, and other conditions using its proprietary lotilaner platform.
Where is Tarsus Pharmaceuticals, Inc. headquartered?
Tarsus Pharmaceuticals, Inc. is headquartered in Irvine, California (15440 Laguna Canyon Road, Irvine, California, 92618).
When was Tarsus Pharmaceuticals, Inc. founded?
Tarsus Pharmaceuticals, Inc. was founded in 2017.
How big is Tarsus Pharmaceuticals, Inc.?
Tarsus Pharmaceuticals, Inc. has an estimated 200-500 employees, with revenue in the $250-500M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
